[Federal Register Volume 88, Number 140 (Monday, July 24, 2023)]
[Proposed Rules]
[Pages 47404-47407]
[FR Doc No: 2023-15378]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. FAA-2023-1216; Project Identifier AD-2023-00502-E]
RIN 2120-AA64

Airworthiness Directives; CFM International, S.A. Engines

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Notice of proposed rulemaking (NPRM).

-----------------------------------------------------------------------

SUMMARY: The FAA proposes to adopt a new airworthiness directive (AD)
for all CFM International, S.A. (CFM) Model LEAP-1B21, LEAP-1B23, LEAP-
1B25, LEAP-1B27, LEAP-1B28, LEAP-1B28B1, LEAP-1B28B2, LEAP-1B28B2C,
LEAP-1B28B3, LEAP-1B28BBJ1, and LEAP-1B28BBJ2 (LEAP-1B) engines. This
proposed AD was prompted by a manufacturer investigation that revealed
that certain high-pressure turbine (HPT) rotor stage 1 disks (HPT stage
1 disks) and a certain compressor rotor stages 6-10 spool were
manufactured from material suspected to have reduced material
properties due to iron inclusion. This proposed AD would require
replacement of certain HPT stage 1 disks and a certain compressor rotor
stages 6-10 spool. The FAA is proposing this AD to address the unsafe
condition on these products.

DATES: The FAA must receive comments on this proposed AD by September
7, 2023.

ADDRESSES: You may send comments, using the procedures found in 14 CFR
11.43 and 11.45, by any of the following methods:
     Federal eRulemaking Portal: Go to regulations.gov. Follow
the instructions for submitting comments.
     Fax:<PHONE_NUMBER>.
     Mail: U.S. Department of Transportation, Docket
Operations, M-

30, West Building Ground Floor, Room W12-140, 1200 New Jersey Avenue
SE, Washington, DC 20590.
     Hand Delivery: Deliver to Mail address above between 9
a.m. and 5 p.m., Monday through Friday, except Federal holidays.
    AD Docket: You may examine the AD docket at regulations.gov by
searching for and locating Docket No. FAA-2023-1216; or in person at
Docket Operations between 9 a.m. and 5 p.m., Monday through Friday,
except Federal holidays. The AD docket contains this NPRM, any comments
received, and other information. The street address for Docket
Operations is listed above.
    Material Incorporated by Reference:
     For service information identified in this NPRM, contact
CFM International, S.A., GE Aviation Fleet Support, 1 Neumann Way, M/D
Room 285, Cincinnati, OH 45215; phone:<PHONE_NUMBER>; email:
[email protected].
     You may view this service information at the FAA,
Airworthiness Products Section, Operational Safety Branch, 1200
District Avenue, Burlington, MA 01803. For information on the
availability of this material at the FAA, call<PHONE_NUMBER>.

FOR FURTHER INFORMATION CONTACT: Mehdi Lamnyi, Aviation Safety
Engineer, FAA, 2200 South 216th Street, Des Moines, WA 98198; phone:
(781) 238-7743; email: [email protected].

SUPPLEMENTARY INFORMATION:

Comments Invited

    The FAA invites you to send any written relevant data, views, or
arguments about this proposal. Send your comments to an address listed
under ADDRESSES. Include ``Docket No. FAA-2023-1216; Project Identifier
AD-2023-00502-E'' at the beginning of your comments. The most helpful
comments reference a specific portion of the proposal, explain the
reason for any recommended change, and include supporting data. The FAA
will consider all comments received by the closing date and may amend
this proposal because of those comments.
    Except for Confidential Business Information (CBI) as described in
the following paragraph, and other information as described in 14 CFR
11.35, the FAA will post all comments received, without change, to
regulations.gov, including any personal information you provide. The
agency will also post a report summarizing each substantive verbal
contact received about this NPRM.

Confidential Business Information

    CBI is commercial or financial information that is both customarily
and actually treated as private by its owner. Under the Freedom of
Information Act (FOIA) (5 U.S.C. 552), CBI is exempt from public
disclosure. If your comments responsive to this NPRM contain commercial
or financial information that is customarily treated as private, that
you actually treat as private, and that is relevant or responsive to
this NPRM, it is important that you clearly designate the submitted
comments as CBI. Please mark each page of your submission containing
CBI as ``PROPIN.'' The FAA will treat such marked submissions as
confidential under the FOIA, and they will not be placed in the public
docket of this NPRM. Submissions containing CBI should be sent to Mehdi
Lamnyi, Aviation Safety Engineer, FAA, 2200 South 216th Street, Des
Moines, WA 98198. Any commentary that the FAA receives which is not
specifically designated as CBI will be placed in the public docket for
this rulemaking.

Background

    The FAA was notified by the manufacturer of the detection of iron
inclusion in three non-LEAP-1B HPT rotor disks. Further investigation
by the manufacturer determined that the iron inclusion is attributed to
deficiencies in the manufacturing process. The investigation by the
manufacturer also determined that certain LEAP-1B HPT stage 1 disks and
a certain compressor rotor stages 6-10 spool manufactured using the
same process may have reduced material properties and a lower fatigue
life capability due to iron inclusion, which may cause premature
fracture and subsequent uncontained failure of certain HPT stage 1
disks and a certain compressor rotor stages 6-10 spool. This condition,
if not addressed, could result in uncontained debris release, damage to
the engine, and damage to the aircraft.

FAA's Determination

    The FAA is issuing this NPRM after determining that the unsafe
condition described previously is likely to exist or develop on other
products of the same type design.

Related Service Information Under 1 CFR Part 51

    The FAA reviewed CFM Service Bulletin LEAP-1B-72-00-0392-01A-930A-
D, Issue 001, dated March 7, 2023. This service information identifies
the part numbers and serial numbers of HPT stage 1 disks and a
compressor rotor stages 6-10 spool with potentially reduced material
properties and specifies procedures for replacement of these parts.
This service information is reasonably available because the interested
parties have access to it through their normal course of business or by
the means identified in ADDRESSES.

Proposed AD Requirements in This NPRM

    This proposed AD would require replacement of certain HPT stage 1
disks and a certain compressor rotor stages 6-10 spool. This proposed
AD would also prohibit installation of an HPT stage 1 disk or
compressor rotor stages 6-10 spool that has a part number and serial
number identified in the service information onto any engine.

Costs of Compliance

    The FAA estimates that this AD, if adopted as proposed, would
affect 39 engines installed on airplanes of U.S. registry. These 39
engines would require replacement of the HPT stage 1 disk. The FAA
estimates that there are no engines installed on airplanes of U.S.
registry that would require replacement of the compressor rotor stages
6-10 spool.
    The FAA estimates the following costs to comply with this proposed
AD:

                                                 Estimated Costs
----------------------------------------------------------------------------------------------------------------
                                                                                Cost per      Cost on U.S.
              Action                      Labor cost             Parts cost           product        operators
----------------------------------------------------------------------------------------------------------------
Replace HPT stage 1 disk..........  8 work-hours x $85     $215,635 (pro-rated).        $216,315      $8,436,285
                                     per hour = $680.
Replace compressor rotor stages 6-  8 work-hours x $85     $37,660 (pro-rated)..          38,340               0
 10 spool.                           per hour = $680.
----------------------------------------------------------------------------------------------------------------

Authority for This Rulemaking

    Title 49 of the United States Code specifies the FAA's authority to
issue rules on aviation safety. Subtitle I, section 106, describes the
authority of the FAA Administrator. Subtitle VII: Aviation Programs,
describes in more detail the scope of the Agency's authority.
    The FAA is issuing this rulemaking under the authority described in
Subtitle VII, Part A, Subpart III, Section 44701: General requirements.
Under that section, Congress charges the FAA with promoting safe flight
of civil aircraft in air commerce by prescribing regulations for
practices, methods, and procedures the Administrator finds necessary
for safety in air commerce. This regulation is within the scope of that
authority because it addresses an unsafe condition that is likely to
exist or develop on products identified in this rulemaking action.

Regulatory Findings

    The FAA determined that this proposed AD would not have federalism
implications under Executive Order 13132. This proposed AD would not
have a substantial direct effect on the States, on the relationship
between the national government and the States, or on the distribution
of power and responsibilities among the various levels of government.
    For the reasons discussed above, I certify this proposed
regulation:
    (1) Is not a ``significant regulatory action'' under Executive
Order 12866,
    (2) Would not affect intrastate aviation in Alaska, and
    (3) Would not have a significant economic impact, positive or
negative, on a substantial number of small entities under the criteria
of the Regulatory Flexibility Act.

List of Subjects in 14 CFR Part 39

    Air transportation, Aircraft, Aviation safety, Incorporation by
reference, Safety.

The Proposed Amendment

    Accordingly, under the authority delegated to me by the
Administrator, the FAA proposes to amend 14 CFR part 39 as follows:

PART 39--AIRWORTHINESS DIRECTIVES

0
1. The authority citation for part 39 continues to read as follows:

    Authority: 49 U.S.C. 106(g), 40113, 44701.

Sec.  39.13  [Amended]

0
2. The FAA amends Sec.  39.13 by adding the following new airworthiness
directive:

CFM International, S.A.: Docket No. FAA-2023-1216; Project
Identifier AD-2023-00502-E.

(a) Comments Due Date

    The FAA must receive comments on this airworthiness directive
(AD) by September 7, 2023.

(b) Affected ADs

    None.

(c) Applicability

    This AD applies to CFM International, S.A. (CFM) Model LEAP-
1B21, LEAP-1B23, LEAP-1B25, LEAP-1B27, LEAP-1B28, LEAP-1B28B1, LEAP-
1B28B2, LEAP-1B28B2C, LEAP-1B28B3, LEAP-1B28BBJ1, and LEAP-1B28BBJ2
engines.

(d) Subject

    Joint Aircraft System Component (JASC) Code 7230, Turbine Engine
Compressor Section; 7250, Turbine Section.

(e) Unsafe Condition

    This AD was prompted by a manufacturer investigation that
revealed that certain high-pressure turbine (HPT) rotor stage 1
disks (HPT stage 1 disks) and a certain compressor rotor stages 6-10
spool were manufactured from material suspected to have reduced
material properties due to iron inclusion. The FAA is issuing this
AD to prevent fracture and subsequent uncontained failure of certain
HPT stage 1 disks and a certain compressor rotor stages 6-10 spool.
The unsafe condition, if not addressed, could result in uncontained
debris release, damage to the engine, and damage to the aircraft.

(f) Compliance

    Comply with this AD within the compliance times specified,
unless already done.

(g) Required Actions

    (1) For engines with an installed HPT stage 1 disk having a part
number (P/N) and serial number (S/N) identified in Compliance,
paragraph 3.E., Tables 1 through 2, of CFM Service Bulletin (SB)
LEAP-1B-72-00-0392-01A-930A-D, Issue 001, dated March 7, 2023 (CFM
SB LEAP-1B-72-00-0392-01A-930A-D): At the next piece-part exposure
of the HPT stage 1 disk, or before exceeding the applicable cycles
since new (CSN) threshold identified in Compliance, paragraph 3.E.,
Tables 1 through 2, of CFM SB LEAP-1B-72-00-0392-01A-930A-D,
whichever occurs first after the effective date of this AD; or if
the applicable CSN threshold has been exceeded as of the effective
date of this AD, within 50 flight cycles (FCs) from the effective
date of this AD; remove the HPT stage 1 disk from service and
replace with a part eligible for installation.
    (2) For engines with an installed compressor rotor stages 6-10
spool having a P/N and S/N identified in Compliance, paragraph 3.E.,
Table 3, of CFM SB LEAP-1B-72-00-0392-01A-930A-D: At the next piece-
part exposure of the compressor rotor stages 6-10 spool, or before
exceeding the applicable CSN threshold identified in Compliance,
paragraph 3.E., Table 3, of CFM SB LEAP-1B-72-00-0392-01A-930A-D,
whichever occurs first after the effective date of this AD; or if
the applicable CSN threshold has been exceeded as of the effective
date of this AD, within 50 FCs from the effective date of this AD;
remove the compressor rotor stages 6-10 spool from service and
replace with a part eligible for installation.

(h) Definition

    For the purpose of this AD, a ``part eligible for installation''
is an HPT stage 1 disk or compressor rotor stages 6-10 spool that
does not have a P/N and S/N identified in Compliance, paragraph
3.E., Tables 1 through 3 of CFM SB LEAP-1B-72-00-0392-01A-930A-D.

(i) Installation Prohibition

    After the effective date of this AD, do not install an HPT stage
1 disk or compressor rotor stages 6-10 spool that has a P/N and S/N
identified in Compliance, paragraph 3.E., Tables 1 through 3 of CFM
SB LEAP-1B-72-00-0392-01A-930A-D.

(j) Alternative Methods of Compliance (AMOCs)

    (1) The Manager, AIR-520 Continued Operational Safety Branch,
FAA, has the authority to approve AMOCs for this AD, if requested
using the procedures found in 14 CFR 39.19. In accordance with 14
CFR 39.19, send your request to your principal inspector or local
Flight Standards District Office, as appropriate. If sending
information directly to the manager of the certification office,
send it to the attention of the person identified in paragraph (k)
of this AD and email to: [email protected].
    (2) Before using any approved AMOC, notify your appropriate
principal inspector, or lacking a principal inspector, the manager
of the local flight standards district office/certificate holding
district office.

(k) Related Information

    For more information about this AD, contact Mehdi Lamnyi,
Aviation Safety Engineer, FAA, 2200 South 216th Street, Des Moines,
WA 98198; phone:<PHONE_NUMBER>; email: [email protected]

(l) Material Incorporated by Reference

    (1) The Director of the Federal Register approved the
incorporation by reference (IBR) of the service information listed
in this paragraph under 5 U.S.C. 552(a) and 1 CFR part 51.
    (2) You must use this service information as applicable to do
the actions required by this AD, unless the AD specifies otherwise.
    (i) CFM International, S.A. Service Bulletin LEAP-1B-72-00-0392-
01A-930A-D, Issue 001, dated March 7, 2023.
    (ii) [Reserved]
    (3) For service information identified in this AD, contact CFM
International, S.A., GE Aviation Fleet Support, 1 Neumann Way, M/D
Room 285, Cincinnati, OH 45215; phone:<PHONE_NUMBER>; email:
[email protected].

    (4) You may view this service information at FAA, Airworthiness
Products Section, Operational Safety Branch, 1200 District Avenue,
Burlington, MA 01803. For information on the availability of this
material at the FAA, call<PHONE_NUMBER>.
    (5) You may view this service information that is incorporated
by reference at the National Archives and Records Administration
(NARA). For information on the availability of this material at
NARA, email: [email protected], or go to: www.archives.gov/federal-register/cfr/ibr-locations.html.

    Issued on June 12, 2023.
Ross Landes,
Deputy Director for Regulatory Operations, Compliance & Airworthiness
Division, Aircraft Certification Service.
[FR Doc. 2023-15378 Filed 7-21-23; 8:45 am]
BILLING CODE 4910-13-P


[Federal Register: November 18, 2009 (Volume 74, Number 221)]
[Notices]
[Page 59568-59569]
[DOCID:fr18no09-75]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2009-N-0143]

Risk Evaluation and Mitigation Strategies for Certain Opioid
Drugs; Notice of Public Meeting

AGENCY:  Food and Drug Administration, HHS.

ACTION:  Notice of public meeting.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing a meeting
with sponsors of certain opioid drug products regarding the development
of Risk Evaluation and Mitigation Strategies (REMS) for these products.
Other members of the public are invited to attend and observe. The REMS
is intended to ensure that the benefits of these drugs continue to
outweigh certain risks. FDA has encouraged affected sponsors to work
collectively to develop a proposed REMS. The purpose of this meeting is
to hear from sponsors about the status of the development of a proposed
REMS and their views regarding the specific features of the REMS for
these products. To promote transparency of the REMS development
process, other members of the public are invited to attend the meeting
as observers. Additional opportunities for public input will be
provided before FDA finalizes the elements of the REMS.

DATES:  The meeting will be held on December 4, 2009, from 9 a.m. to 1
p.m. To ensure consideration at the meeting, submit comments by
November 27, 2009. Register to attend the meeting by November 27, 2009.
See section III of this document for information on how to register for
the meeting.

ADDRESSES:  The public meeting will be held at the Holiday Inn
Washington-College Park, 10000 Baltimore Ave., College Park, MD 20740.
    Submit written comments to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061.
Rockville, MD 20852. Submit electronic comments to http://
www.regulations.gov. All comments should be identified with the docket
number found in brackets in the heading of this document.
    A live webcast of this meeting will be viewable at http://
ConnectLive.com/events/fda120409 on the day of the meeting. A video
record of the meeting will be available at the same Web address for 1
year.

FOR FURTHER INFORMATION CONTACT:  Theresa (Terry) Martin, Center for
Drug Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, rm. 6196, Silver Spring, MD 20993, 301-796-
3448, FAX:<PHONE_NUMBER>, or
    Patrick Frey, Center for Drug Evaluation and Research, Food and
Drug Administration, 10903 New Hampshire Ave., Bldg. 51, rm. 6350,
Silver Spring, MD 20993,<PHONE_NUMBER>, FAX:<PHONE_NUMBER>, e-mail:
<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION:

I. Background

    On February 6, 2009, the Food and Drug Administration (FDA) sent
letters to manufacturers of certain opioid drug products, indicating
that these drugs will be required to have a Risk Evaluation and
Mitigation Strategy (REMS) to ensure that the benefits of the drugs
continue to outweigh the risks. A table of opioid products that will be
required to have REMS is available on the agency's Web site at http://
www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm163654.htm.
Copies of this document may be requested from Theresa (Terry) Martin
(see FOR FURTHER INFORMATION CONTACT). The affected opioid drugs
include brand name and generic products and are formulated with the
active ingredients fentanyl, hydromorphone, methadone, morphine,
oxycodone, and oxymorphone. The REMS would be intended to ensure that
the benefits of these drugs continue to outweigh the risks associated
with: (1) Use of high doses of long-acting opioids and extended-release
opioid products in non-opioid-tolerant and inappropriately selected
individuals; (2) abuse; (3) misuse; and (4) overdose, both accidental
and intentional. REMS for these opioids would likely include elements
to assure safe use to ensure that prescribers, dispensers, and patients
are aware of, and understand, the risks and how these products should
be used.
    On March 3, 2009, FDA held a meeting with affected sponsors to
discuss how the REMS could be designed to manage the risks while also
minimizing burdens to the health care system. FDA presented a high-
level overview, regulatory background, and the proposed elements of the
REMS followed by questions and comments from the sponsors. At this
meeting, FDA encouraged sponsors to work collectively to develop a
proposed REMS. The FDA presentations and minutes from this meeting are
available on the agency's Web site at http://www.fda.gov/Drugs/
DrugSafety/InformationbyDrugClass/ucm163660.htm. In May, FDA held
meetings with other affected stakeholders including health care
professionals, patient advocates, and pharmacy groups. FDA then held a
public meeting on May 27 and 28, 2009, where FDA heard from members of
the public on what the REMS should look like for these products, how to
minimize the burden on the health care community and patients, and how
FDA should evaluate the REMS to determine whether it achieves its
objectives. Nearly 100 members of the public spoke at the meeting, and
many others have submitted written comments to the docket (Docket No.
FDA-2009-N-0143). For additional background information about this
issue see 74 FR 17967, April 20, 2009.

II. Purpose of Meeting

    The purpose of this meeting is for FDA to hear from sponsors of
long-acting opioids and extended-release opioid products on the
development of the REMS for these products and their views about the
specific features of the REMS. Other members of the public are invited
to attend the meeting as observers. Because this is a meeting between
FDA staff and the sponsors, only FDA staff will be permitted to
question the sponsors at the meeting. However, interested persons who
attend the public meeting will be given an opportunity to provide
suggestions for questions for FDA staff to ask the sponsors, at FDA's
sole discretion. Index cards will be provided for this purpose. There
will be additional opportunities for public input before FDA finalizes
the elements of the REMS.

III. Attendance and Registration

    Registration: Register by e-mail to<EMAIL_ADDRESS>Provide
complete contact information for each attendee, including name, title,
affiliation, address, e-mail, and phone

number. Registration requests should be received by November 27, 2009.
Registration is free and will be on a first-come, first-served basis.
Early registration is recommended because seating is limited. FDA may
limit the number of participants from each organization based on space
limitations. Registrants will receive confirmation once they have been
accepted. Onsite registration on the day of the meeting will be based
on space availability on the day of the event starting at 8 a.m.
    If you need special accommodations because of disability, please
contact Theresa (Terry) Martin (see FOR FURTHER INFORMATION CONTACT) at
least 7 days before the meeting.
    In addition, a live webcast of this meeting will be viewable at
http://ConnectLive.com/events/fda120409 on the day of the meeting. A
video record of the meeting will be available at the same Web address
for 1 year.

IV. Comments

    In addition, any person may submit written or electronic comments
to the Division of Dockets Management (see DATES and ADDRESSES). Submit
a single copy of electronic comments or two paper copies of any mailed
comments, except that individuals may submit one paper copy. Comments
are to be identified with the docket number found in brackets in the
heading of this document. Received comments may be seen in the Division
of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

V. Transcripts

    Transcripts of the meeting will be available for review at the
Division of Dockets Management and on the Internet at http://
www.regulations.gov approximately 30 days after the meeting. A
transcript will also be made available in either hard copy or on CD-
ROM, upon submission of a Freedom of Information request. Written
requests are to be sent to Division of Freedom of Information (HFI-35),
Office of Management Programs, Food and Drug Administration, 5600
Fishers Lane, rm. 6-30, Rockville, MD 20857.

    Dated: November 12, 2009.
David Horowitz,
Assistant Commissioner for Policy.
[FR Doc. E9-27718 Filed 11-17-09; 8:45 am]

BILLING CODE 4160-01-S


[Federal Register Volume 80, Number 23 (Wednesday, February 4, 2015)]
[Notices]
[Pages 6085-6086]
[FR Doc No: 2015-02209]

-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[EPA-HQ-OPP-2015-0021; FRL-9921-97]

Pesticide Product Registration; Receipt of Applications for New
Active Ingredients

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: EPA has received applications to register pesticide products
containing active ingredients not included in any currently registered
pesticide products. Pursuant to the Federal Insecticide, Fungicide, and
Rodenticide Act (FIFRA), EPA is hereby providing notice of receipt and
opportunity to comment on these applications.

DATES: Comments must be received on or before March 6, 2015.

ADDRESSES: Submit your comments, identified by docket identification
(ID) number and the File Symbol of interest as shown in the body of
this document, by one of the following methods:
     Federal eRulemaking Portal: http://www.regulations.gov.
Follow the online instructions for submitting comments. Do not submit
electronically any information you consider to be Confidential Business
Information (CBI) or other information whose disclosure is restricted
by statute.
     Mail: OPP Docket, Environmental Protection Agency Docket
Center (EPA/DC), (28221T), 1200 Pennsylvania Ave. NW., Washington, DC
20460-0001.
     Hand Delivery: To make special arrangements for hand
delivery or delivery of boxed information, please follow the
instructions at http://www.epa.gov/dockets/contacts.html.
    Additional instructions on commenting or visiting the docket, along
with more information about dockets generally, is available at http://www.epa.gov/dockets.

FOR FURTHER INFORMATION CONTACT: Robert McNally, Biopesticides and
Pollution Prevention Division (BPPD) (7511P), main telephone number:
(703) 305-7090; email address<EMAIL_ADDRESS>Susan Lewis,
Registration Division (RD) (7505P), main telephone number: (703) 305-
7090; email address<EMAIL_ADDRESS>The mailing address is:
Office of Pesticide Programs, Environmental Protection Agency, 1200
Pennsylvania Ave. NW., Washington, DC 20460-0001. As part of the
mailing address, include the contact person's name, division, and mail
code. The division to contact is listed at the end of each application
summary.

SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this action apply to me?

    You may be potentially affected by this action if you are an
agricultural producer, food manufacturer, or pesticide manufacturer.
The following list of North American Industrial Classification System
(NAICS) codes is not intended to be exhaustive, but rather provides a
guide to help readers determine whether this document applies to them.
Potentially affected entities may include:
     Crop production (NAICS code 111).
     Animal production (NAICS code 112).
     Food manufacturing (NAICS code 311).
     Pesticide manufacturing (NAICS code 32532).

B. What should I consider as I prepare my comments for EPA?

    1. Submitting CBI. Do not submit this information to EPA through
regulations.gov or email. Clearly mark the part or all of the
information that you claim to be CBI. For CBI information in a disk or
CD-ROM that you mail to EPA, mark the outside of the disk or CD-ROM as
CBI and then identify electronically within the disk or CD-ROM the
specific information that is claimed as CBI. In addition to one
complete version of the comment that includes information claimed as
CBI, a copy of the comment that does not contain the information
claimed as CBI must be submitted for inclusion in the public docket.
Information so marked will not be disclosed except in accordance with
procedures set forth in 40 CFR part 2.
    2. Tips for preparing your comments. When preparing and submitting
your comments, see the commenting tips at http://www.epa.gov/dockets/comments.html.

II. Registration Applications

    EPA has received applications to register pesticide products
containing active ingredients not included in any

currently registered pesticide products. Pursuant to the provisions of
FIFRA section 3(c)(4) (7 U.S.C. 136a(c)(4)), EPA is hereby providing
notice of receipt and opportunity to comment on these applications.
Notice of receipt of these applications does not imply a decision by
the Agency on these applications.
    1. File Symbol: 70051-RRI. Docket ID number: EPA-HQ-OPP-2015-0007.
Applicant: Certis USA L.L.C., 9145 Guilford Rd., Suite 175, Columbia,
MD 21046. Product name: BmJ TGAI. Active ingredient: Fungicide and
Bacillus mycoides isolate J at 100%. Proposed classification/Use:
Manufacturing use. Contact: BPPD.
    2. File Symbol: 70051-RRO. Docket ID number: EPA-HQ-OPP-2015-0007.
Applicant: Certis USA L.L.C., 9145 Guilford Rd., Suite 175, Columbia,
MD 21046. Product name: BmJ WG. Active ingredient: Fungicide that also
claims to reduce plant viral infections and Bacillus mycoides isolate J
at 40.0%. Proposed classification/Use: Almonds, citrus, cole crops,
cucurbits, fruiting vegetables, grapes, legumes, lettuce, pecans, pome
fruits, potatoes, spinach, and sugarbeets. Contact: BPPD.
    3. File Symbol: 88031-EE. Docket ID number: EPA-HQ-OPP-2015-0023.
Applicant: CP Bio, Inc., 4802 Murrieta St., Chino, CA 91710. Product
name: Choline Chloride Technical. Active ingredient: Biochemical Plant
Growth Regulator and Choline Chloride (Acetyl Choline) at 98%. Proposed
classification/Use: Manufacturing Use Product to be Formulated into
Plant Growth Regulator End Use Products. Contact: BPPD.
    4. File Symbol: 88031-EG. Docket ID number: EPA-HQ-OPP-2015-0023.
Applicant: CP Bio, Inc., 4802 Murrieta St., Chino, CA 91710. Product
name: Choline Chloride 20% SP. Active ingredient: Biochemical Plant
Growth Regulator and Choline Chloride (Acetyl Choline) at 20%. Proposed
classification/Use: Plant Growth Regulator for Amelioration of Growth
Reduction Caused by Sodic Soils. Contact: BPPD.
    5. File Symbol: 91266-R. Docket ID number: EPA-HQ-OPP-2015-0043.
Applicant: United States Department of Agriculture, 10300 Baltimore
Ave., Bld. 306 BARC-EAST, Beltsville, Maryland 20705. Product name:
Oxalic Acid Dihydrate. Active ingredient: Oxalic Acid Dihydrate at
100%. Proposed classification/Use: Insecticide/in-hive use to control
Varroa mites. Contact: RD.

    Authority: 7 U.S.C. 136 et seq.

    Dated: January 27, 2015.
Robert NcNally,
Director, Biopesticides and Pollution Prevention Division, Office of
Pesticide Programs.
[FR Doc. 2015-02209 Filed 2-3-15; 8:45 am]
BILLING CODE 6560-50-P